R&D | January 02, 2025
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
Subscribe To Our Newsletter & Stay Updated
